Skip to main navigation menu Skip to main content Skip to site footer
FrancoAngeli Journals

Saggi, Studi e Ricerche

No. 49 (2018)

Position Paper

Submitted
gennaio 5, 2018
Published
2018-02-23

Abstract

The data recently published in scientific literature identify in substance abuse the most important risk factor for the transmission of HCV. Another population at risk is represented by detainees, mainly because most of them have a history of substance use.
Treatment of the population at risk (substance users and detainees) must become a priority for health systems both to ensure fairness of access to care and to achieve the public health goal of eliminating HCV.
The programs to take charge should be multi-disciplinary, flexible, tailored, evidence-based, disseminated homogeneously throughout the national territory, and supported by procedures and guidelines including harm reduction actions, as suggested by the WHO.

References

  1. AIFA (2017). Criteri di trattamento per l’epatite C. -- www.agenziafarmaco.gov.it/content/aggiornamento-epatite-c.
  2. Aspinall E.J., Corson S., Dovle J.S., Grebely J., Hutchinson S.J., Dore G.J., Goldberg D.J., Hellard M.E. (2013). Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin. Infect. Dis., 57(Suppl 2): S80-9.
  3. Batchelder A.W., Peyser D., Nahvi S., Arnsten J.H., Litwin A.H. (2015). Hepatitis C treatment turned me around: “Psychological and behavioral transformation related to hepatitis C treatment”. Drug Alcohol Depend., 153: 66-71.
  4. Bielen R., Moreno C., Van Vlierberghe H., Bourgeois S., Mulkay J.P., Vanwolleghem T., Verlinden W., Brixko C., Decaestecker J., De Galocsy C., Janssens F., Cool M., Van Steenkiste C., D’heygere F., Cools W., Nevens F., Robaeys G. (2017). Belgian experience with direct acting antivirals in people who inject drugs. Drug Alcohol
  5. Depend., 177: 214-220.
  6. Dillon J.F., Lazarus J.V., Razavi H.A. (2016). Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatology Medicine and Policy, 1: 2.
  7. European Monitoring Centre for Drug and Drug Addiction (EMCDDA) European C among drug users in Europe, epidemiology, treatment and prevention (2016). www.emcdda.europa.eu/system/files/publications/2953/TDXD16002ENN_final_web.pdf.
  8. Hawk M., Coulter R.W.S., Egan J.E., Fisk S., Reuel Friedman M., Tula M., Kinsky S. (2017). Harm reduction principles for healthcare settings. Harm Reduct. J., 14(1): 70.
  9. Konerman M.A., Lok A.S.F. (2016). Hepatitis C treatment and barriers to eradication. Clin. Transl. Gastroenterology, 7: e193.
  10. Magiorkinis G., Sypsa V., Magiorkinis E., Paraskevis D., Katsoulidou A., Belshaw R., Fraser C., Pybus O.G., Hatzakis A. (2013). Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics. PLoS Comput Biol., 9(1): e1002876.
  11. Martin N.K., Vickerman P., Dore G., Hickman M. (2015). The HCV epidemics in key populations (including PWID, prisoners, and MSM): the use of DAAs as treatment for prevention. Curr Opin HIV AIDS, 10: 374-380.
  12. Metzig C., Surey J., Francis M., Conneely J., Abubakar I., White P.J. (2017). Impact of hepatitis C treatment as prevention for people who inject drug is sensitive to contact network structure. Sci Rep. 2017, May 12, 7(1): 1833.
  13. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., Degenhardt L. (2011). Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet, 378(9791): 571-83.
  14. Relazione Annuale al Parlamento sullo Stato delle Tossicodipendenze, anno 2017, www.politicheantidroga.gov.it/media/2153/relazione-alparlamento_2017.pdf.
  15. Rich Z.C., Chu C., Mao J., Zhou K., Cai W., Ma Q., Volberding P., Tucker J.D. (2016). Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals. BMC Public Health, 16: 994.
  16. Schaefer M., Capuron L., Friebe A., Diez-Quevedo C., obaeys G., Neri S., Foster G.R., Kautz A., Forton D., Pariante C.M. (2012). Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J. Hepathol., 57: 1379-1390.
  17. Stroffolini T., D’Egidio P.F., Aceti A., Filippini P., Puoti M., Leonardi C., Almasio P.L., DAVIS Drug Addicted, HCV Prevalence in Italy an Epidemiological, Observational, Cross-Sectional, Multicenter Study Participating Centers (2012). Hepatitis C virus infection among drug addicts in Italy. J. Med. Virol., 84: 1608-1612.
  18. UN World Report (2016). www.unodc.org/doc/wdr2016/WORLD_
  19. DRUG_REPORT_2016_web.pdf.
  20. Yarlott L., Heald E., Forton D. (2017). Hepatitis C virus infection, and neurological and psychiatric disorder – a review. J. Adv. Res., 8: 138-148.
  21. World Health Organization, Barriers and facilitators to hepatitis C treatment for people who inject drugs, a qualitative study (2012). www.euro.who.int/__data/assets/pdf_file/0011/179750/Barriers-andfacilitators-to-hepatitis-C-treatment-for-PWID-A-qualitative-study-June-2012-rev-5.pdf?ua=1.
  22. WHO Global Hepatitis Report (2017). http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1.
  23. Wiessing L., Ferri M., Grady B., Kantzanou M., Sperle I., Cullen K.J., EMCDDA DRID group, Hatzakis A., Prins M., Vickerman P., Lazarus J.V., Hope V.D., Mathei C. (2014). PLoS One, 28, 9(7): e103345.
  24. Wolfe D., Luhmann N., Harris M., Momenghalibaf A., Albers E., Byrne E., Swan T. (2015). Human rights to access to hepatitis C treatment for people who inject drugs. Inter. J. Drug Policy, 26: 1072-1080.
  25. Zampino R., Coppola N., Sagnelli C., Di Caprio G., Sagnelli E. (2015). Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment. World J Hepatol., 7(21): 2323-30.

Metrics

Metrics Loading ...